- At the European Cancer Congress, Ariad Pharmaceuticals (ARIA) gives an update on the Phase 1/2 trial of AP26113.
- According to the company, the tyrosine kinase inhibitor demonstrated "robust anti-tumor activity" in patients with TKI-naïve and crizotinib-resistant ALK+ non-small cell lung cancer.
- Additionally, it appears the drug is active in patients with brain metastases. (PR)
Ariad says AP26113 continues to show promise in advanced NSCLC
Sep 28 2013, 22:08 ET